146 related articles for article (PubMed ID: 36893690)
21. Safe and Effective Kinase Inhibitors for the Treatment of Gynecological Cancers: In Silico Approach.
Patil VM; Kumar A; Anand V; Bansal P; Masand N
Curr Drug Metab; 2021; 22(7):537-549. PubMed ID: 33797363
[TBL] [Abstract][Full Text] [Related]
22. Novel membrane-based targets - Therapeutic potential in gynecological cancers.
Gizzi M; Pautier P; Lhomme C; Leary A
Crit Rev Oncol Hematol; 2015 Mar; 93(3):293-303. PubMed ID: 25523485
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel Wee1 isoform.
Yu Y; Chen B; Chen Z; Fan C; Han Y; Zhang J; He L; Ingram A; Kapoor A; Wang JH; Tang D
Biochim Biophys Acta; 2005 May; 1729(1):1-9. PubMed ID: 15804487
[TBL] [Abstract][Full Text] [Related]
24. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Cuneo KC; Morgan MA; Sahai V; Schipper MJ; Parsels LA; Parsels JD; Devasia T; Al-Hawaray M; Cho CS; Nathan H; Maybaum J; Zalupski MM; Lawrence TS
J Clin Oncol; 2019 Oct; 37(29):2643-2650. PubMed ID: 31398082
[TBL] [Abstract][Full Text] [Related]
25. Use of anticancer agents in gynecological oncology during pregnancy: a systematic review of maternal pharmacokinetics and transplacental transfer.
Berveiller P; Marty O; Vialard F; Mir O
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):523-31. PubMed ID: 27020922
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
Metzler JM; Burla L; Fink D; Imesch P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532074
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. DNA damage response as a therapeutic target in gynecological cancers.
Leary A; Auguste A; Mesnage S
Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in gynecological cancers: where are we?
Polastro L; Closset C; Kerger J
Curr Opin Oncol; 2020 Sep; 32(5):459-470. PubMed ID: 32675594
[TBL] [Abstract][Full Text] [Related]
34. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma.
Liu J; Oza AM; Colombo N; Oaknin A
Int J Gynecol Cancer; 2022 Jan; 32(1):89-92. PubMed ID: 34716177
[TBL] [Abstract][Full Text] [Related]
35. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
38. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
39. FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.
Diab A; Gem H; Swanger J; Kim HY; Smith K; Zou G; Raju S; Kao M; Fitzgibbon M; Loeb KR; Rodriguez CP; Méndez E; Galloway DA; Sidorova JM; Clurman BE
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28287-28296. PubMed ID: 33093209
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
